Glenmark Pharmaceuticals liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

6.83×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.77×	1.77×	1.56×	1.28×	1.96×
1.23×	1.23×	1.05×	0.84×	1.37×
1,175	1,175	1,676	1,658	1,443
4,923	4,923	3,328	1,609	4,828

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GLENMARK₹2,339.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersDRREDDY LUPIN ALKEM BIOCON MANKIND LAURUSLABS FORTIS AUROPHARMAMcap ₹66,007 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	6.83
Current Ratio	1.96	1.28	1.56	1.77	1.77
Quick Ratio	1.37	0.84	1.05	1.23	1.23
Cash, Equiv & ST Investments	1,443.0	1,658.3	1,675.7	1,174.7	1,174.7
Working Capital	4,828.2	1,609.5	3,328.4	4,923.3	4,923.3

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.